• Presented at International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2020

  • Collaborator: Dermatology Center, GEM Resopso, University Sorbonne Paris Nord

  • Authors: Halioua B, Zetlaoui J, Astruc A, Testa D, Bombezin-Domino A, Radoszycki

The COVID-19 pandemic has shrone a light on the vulnerability of people living with pre-existing immune-mediated inflammatory diseases (IMID) and taking a biologic therapy.